Wedoany.com Report-Apr. 9, Novo Nordisk, the Danish pharmaceutical firm known for its obesity drug Wegovy, has revealed plans to invest US$1.09 billion to expand its facility in Minas Gerais, southeast Brazil. This 74,000-square-meter project will support the production of multiple products, including the GLP-1 hormone used in its diabetes treatment Ozempic. The expansion highlights Brazil’s importance as one of the company’s top five markets globally.

Novo Nordisk’s corporate headquarters in Copenhagen

The Montes Claros facility serves as a key hub, exporting to 70 countries. Reinaldo Costa, corporate vice president of the site, described the upgrade as a “considerable and significant increase” in capacity. The expanded factory is scheduled to start operations in 2028, strengthening Novo Nordisk’s ability to meet growing demand for its treatments.

This investment focuses on enhancing production for domestic use and export markets. Brazil’s role as a major market underscores the facility’s strategic value, with the expansion aimed at boosting output rather than shifting reliance on imports. The project will reinforce Novo Nordisk’s global supply chain, leveraging its established presence in the region.

Reinaldo Costa emphasized the scale of the development, noting its impact on the company’s operations. He stated: “considerable and significant increase,” signaling confidence in the project’s ability to elevate production levels. The timeline of 2028 provides a clear target for when the facility will begin contributing to the company’s portfolio, including Wegovy and Ozempic.

Novo Nordisk has also addressed potential concerns about U.S. tariffs raised by President Trump. The company pointed out that it already operates factories in the U.S., with plans for an additional facility announced in June of the previous year. This diversified manufacturing base helps mitigate risks tied to international trade policies, ensuring steady supply across its markets.

The Minas Gerais expansion aligns with Novo Nordisk’s broader strategy to support demand for its GLP-1-based treatments, widely used for obesity and diabetes management. By scaling up in Brazil, the company enhances its capacity to serve both local consumers and its extensive export network. The investment reflects a commitment to maintaining its leadership in the pharmaceutical sector.

Construction of the expanded facility will bolster Brazil’s position within Novo Nordisk’s operations. The project, set to conclude by 2028, promises to deliver advanced production capabilities while sustaining the company’s export activities to 70 countries. This move ensures a robust supply of key medications for years ahead.

Novo Nordisk’s focus remains on meeting market needs efficiently. The US$1.09 billion investment in Montes Claros underscores its proactive approach to growth, balancing local production with global outreach. With existing U.S. facilities and this new Brazilian expansion, the company is well-equipped to navigate trade dynamics while advancing its product offerings.